We’re proud to share that Precede Biosciences has secured $83.5M in total financing to scale our next-generation precision diagnostics platform.
This capital supports continued growth amid strong commercial traction with leading biopharmaceutical developers advancing the next wave of precision medicines. More broadly, this milestone reflects growing conviction in the need for diagnostics built for target expression and pathway biology, the biomarkers most relevant to next-generation precision medicines, including antibody drug conjugates (ADCs), targeted protein degraders, and other next-generation precision medicines.
We’re grateful for the continued support of our existing investors, including Illumina Ventures, 5AM Ventures, Bristol Myers Squibb, Osage University Partners (OUP), Binney Street Capital, and Lilly Asia Ventures, and excited to welcome new strategic and institutional partners, including Labcorp Venture Fund, UPMC Enterprises, Mirae Asset Capital Life Science, Mirae Asset Capital, 28 Capital LLC, and Alexandria Venture Investments.
We’re also grateful for the commitment and belief of the team at SVB, who support the Precede Bio mission through strategic, non-dilutive financing.
Together, this group adds deep expertise to the Precede mission, a mission to meaningfully impact drug development success rates and ensure patients receive treatments fully aligned to the biology of their disease.
View press release: precede.bio/news/seriesb-f…
English
